WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards (ABEA), achieving a historic record for the most accolades received in a single year. These recognitions underscore the company's sustained leadership in end‑to‑end biologics development and manufacturing capabilities, digital innovation and operational excellence.

WuXi Biologics was named the winner in the following categories:

• Best Contract Development & Manufacturing Organization Award
• Best Aseptic Fill-Finish & Packaging CMO of the Year
• Bioprocessing Excellence in Asia
• Bioprocessing Excellence in China
• Bioprocessing Facility of the Year
• Excellence in Bioprocessing Automation & Digitalization

In addition to corporate honors, Dr. Sherry Gu, Chief Technology Officer, Executive Vice President, was named CTO of the Year, in recognition of her outstanding vision, technological innovation, and leadership in advancing biologics development and bioprocessing excellence, and Dr. Jeremy Guo, Head of Global Drug Product Operations, Senior Vice President, received the award of Head of Fill-Finish & Formulation of the Year, honoring his remarkable expertise and dedication in driving high-quality, compliant, and reliable drug product manufacturing and aseptic processing capabilities.

Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, stated, "We are honored to receive this unprecedented number of awards at the 2026 Asia-Pacific Biopharma Excellence Awards. These accolades reflect the trust of our global partners, the expertise of our team, and our unwavering commitment to quality, innovation, and operational excellence. As we continue to scale our integrated CRDMO platform, advance digital and intelligent bioprocessing and manufacturing, we remain committed to accelerating our partners' innovative therapies to patients worldwide."